Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Litha Pharma (Pty) Ltd, 106 16th Road, Midrand, 1686
ESCAPELLE tablet.
| Pharmaceutical Form |
|---|
|
Almost white, flat, rimmed tablet of about 8 mm diameter, with an impression mark of “G00” on one side. |
Each tablet contains 1,50 mg of levonorgestrel.
Contains sugar. Each tablet contains 142.5 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levonorgestrel |
The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest. |
| List of Excipients |
|---|
|
Colloidal silica anhydrous |
The folded carton of ESCAPELLE contains one aluminium/PVC blister of one tablet.
Litha Pharma (Pty) Ltd, 106 16th Road, Midrand, 1686
41/21.8.2/0021
Original date of registration: 08 February 2008
| Drug | Countries | |
|---|---|---|
| ESCAPELLE | Estonia, Hong Kong, Croatia, Lithuania, Malta, Poland, Romania, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
